tetano
Editor, Senior Moderator
Virus Res
. 2022 Dec 13;324:199024.
doi: 10.1016/j.virusres.2022.199024. Online ahead of print.
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2
Xiaoxiao Jin[SUP] 1 [/SUP], Xiaotao Liu[SUP] 2 [/SUP], Chuanlai Shen[SUP] 3 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remains in a global pandemic, and no eradicative therapy is currently available. Host T cells have been shown to play a crucial role in the antiviral immune protection and pathology in Coronavirus disease 2019 (COVID-19) patients; thus, identifying sufficient T-cell epitopes from the SARS-CoV-2 proteome can contribute greatly to the development of T-cell epitope vaccines and the precise evaluation of host SARS-CoV-2-specific cellular immunity. This review presents a comprehensive map of T-cell epitopes functionally validated from SARS-CoV-2 antigens, the human leukocyte antigen (HLA) supertypes to present these epitopes, and the strategies to screen and identify T-cell epitopes. To the best of our knowledge, a total of 1349 CD8[SUP]+[/SUP] T-cell epitopes and 790 CD4[SUP]+[/SUP] T-cell epitopes have been defined by functional experiments thus far, but most are presented by approximately twenty common HLA supertypes, such as HLA-A0201, A2402, B0702, DR15, DR7 and DR11 molecules, and 74-80% of the T-cell epitopes are derived from S protein and nonstructural protein. These data provide useful insight into the development of vaccines and specific T-cell detection systems. However, the currently defined T-cell epitope repertoire cannot cover the HLA polymorphism of major populations in an indicated geographic region. More research is needed to depict an overall landscape of T-cell epitopes, which covers the overall SARS-CoV-2 proteome and global patients.
Keywords: HLA restriction; SARS-CoV-2; T-cell epitope.
. 2022 Dec 13;324:199024.
doi: 10.1016/j.virusres.2022.199024. Online ahead of print.
A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2
Xiaoxiao Jin[SUP] 1 [/SUP], Xiaotao Liu[SUP] 2 [/SUP], Chuanlai Shen[SUP] 3 [/SUP]
Affiliations
- PMID: 36526016
- DOI: 10.1016/j.virusres.2022.199024
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection remains in a global pandemic, and no eradicative therapy is currently available. Host T cells have been shown to play a crucial role in the antiviral immune protection and pathology in Coronavirus disease 2019 (COVID-19) patients; thus, identifying sufficient T-cell epitopes from the SARS-CoV-2 proteome can contribute greatly to the development of T-cell epitope vaccines and the precise evaluation of host SARS-CoV-2-specific cellular immunity. This review presents a comprehensive map of T-cell epitopes functionally validated from SARS-CoV-2 antigens, the human leukocyte antigen (HLA) supertypes to present these epitopes, and the strategies to screen and identify T-cell epitopes. To the best of our knowledge, a total of 1349 CD8[SUP]+[/SUP] T-cell epitopes and 790 CD4[SUP]+[/SUP] T-cell epitopes have been defined by functional experiments thus far, but most are presented by approximately twenty common HLA supertypes, such as HLA-A0201, A2402, B0702, DR15, DR7 and DR11 molecules, and 74-80% of the T-cell epitopes are derived from S protein and nonstructural protein. These data provide useful insight into the development of vaccines and specific T-cell detection systems. However, the currently defined T-cell epitope repertoire cannot cover the HLA polymorphism of major populations in an indicated geographic region. More research is needed to depict an overall landscape of T-cell epitopes, which covers the overall SARS-CoV-2 proteome and global patients.
Keywords: HLA restriction; SARS-CoV-2; T-cell epitope.